Evidence map›Paper›PMID 38937649›Full record

ArticleScientific reports2024

Exploiting the Fc base of IgG antibodies to create functional nanoparticle conjugates.

Mohammed M Al Qaraghuli, Karina Kubiak-Ossowska, Valerie A Ferro, Paul A Mulheran

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Enhancement of Structural Stability and IgG Affinity of aAntibodies (Basel, Switzerland) · 2025
    Article
  2. Advances in Nanomedicine for Precision Insulin Delivery.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohammed M Al QaraghuliEPSRC Future Manufacturing Research Hub for Continuous Manufacturing and Advanced Crystallisation, University of Strathclyde, Glasgow, UK. mohammed.al-qaraghuli@strath.ac.uk.
Karina Kubiak-OssowskaDepartment of Chemical and Process Engineering, University of Strathclyde, 75 Montrose Street, Glasgow, G1 1XJ, UK.
Valerie A FerroStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK.
Paul A MulheranDepartment of Chemical and Process Engineering, University of Strathclyde, 75 Montrose Street, Glasgow, G1 1XJ, UK.

Funding

EPSRC Impact Acceleration Account - University of Strathclyde 2017 EP/R51178X/1
6 · The paper itself

Abstract

The structures of the Fc base of various IgG antibodies have been examined with a view to understanding how this region can be used to conjugate IgG to nanoparticles. The base structure is found to be largely consistent across a range of species and subtypes, comprising a hydrophobic region surrounded by hydrophilic residues, some of which are charged at physiological conditions. In addition, atomistic Molecular Dynamics simulations were performed to explore how model nanoparticles interact with the base using neutral and negatively charged gold nanoparticles. Both types of nanoparticle interacted readily with the base, leading to an adaptation of the antibody base surface to enhance the interactions. Furthermore, these interactions left the rest of the domain at the base of the Fc region structurally intact. This implies that coupling nanoparticles to the base of an IgG molecule is both feasible and desirable, since it leaves the antibody free to interact with its surroundings so that antigen-binding functionality can be retained. These results will therefore help guide future attempts to develop new nanotechnologies that exploit the unique properties of both antibodies and nanoparticles.

Indexed as

GoldImmunoglobulin Fc FragmentsImmunoglobulin GMetal NanoparticlesMolecular Dynamics SimulationAnimalsHumansHydrophobic and Hydrophilic InteractionsNanoparticlesGoldImmunoglobulin Fc FragmentsImmunoglobulin GAntibodyAntibody functionGold nanoparticlesMolecular dynamicsStructural similarity

Identifiers

PMID38937649
PMCPMC11211340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.